PTC Therapeutics (NASDAQ:PTCT) vs. PDS Biotechnology (NASDAQ:PDSB) Financial Survey

PDS Biotechnology (NASDAQ:PDSB) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Volatility & Risk

PDS Biotechnology has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Profitability

This table compares PDS Biotechnology and PTC Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

Earnings and Valuation

This table compares PDS Biotechnology and PTC Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50 million	($0.67)	-1.30
PTC Therapeutics	$1.73 billion	3.90	$682.64 million	($2.33)	-34.91

PTC Therapeutics has higher revenue and earnings than PDS Biotechnology. PTC Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for PDS Biotechnology and PTC Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1	0	2	0	2.33
PTC Therapeutics	2	1	10	1	2.71

PDS Biotechnology currently has a consensus price target of $9.00, suggesting a potential upside of 929.75%. PTC Therapeutics has a consensus price target of $91.36, suggesting a potential upside of 12.30%. Given PDS Biotechnology’s higher possible upside, research analysts plainly believe PDS Biotechnology is more favorable than PTC Therapeutics.

Institutional and Insider Ownership

26.8% of PDS Biotechnology shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

PDS Biotechnology beats PTC Therapeutics on 8 of the 14 factors compared between the two stocks.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

About PTC Therapeutics

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.